Contact Us

•health professionals

TEXT SIZE

Bringing the Experts to You

XIIth International Myeloma Workshop, Day 4, March 1, 2009 08:15-10:15 Pro and Con Session 10:30-12:30 Phase II Studies 13:30-15:00 Plenary Session 15:30-17:30 Future Perspectives/Closing Ceremony Complete Program Listing

print share |

Simultaneous use of Novel Agents in Induction Therapy
	XIIth International Myeloma Workshop in Washington, DC Morie Gertz, M.D. Mayo Clinic Rochester, Minnesota

---

Sequential use of Novel agents in Induction Therapy
	XIIth International Myeloma Workshop in Washington, DC Joan Bladé, M.D. Hospital Clinic Barcelona, Spain

---

Simultaneous vs. Sequential Use of Novel Agents in Induction Therapy
	Rebuttal by Drs. Gertz and Bladé followed by Q & A Period

---

Therapy Should be Based on Risk Satisfaction - Favor
	XIIth International Myeloma Workshop in Washington, DC Angela Dispenzieri, M.D. Mayo Clinic Rochester, Minnesota

---

Therapy Should be Based on Risk Stratification - Against
	XIIth International Myeloma Workshop in Washington, DC Jesus San-Miguel, M.D. University Hospital Salamanca, Spain

---

Should Myeloma Therapy Be Based on Risk Stratification?
	Rebuttal by Drs. Dispenzieri and San Miguel followed by Q & A Period

---

Is there a role for Allo Tx? - Favor
	XIIth International Myeloma Workshop in Washington, DC Jayesha Mehta, M.D. Northwestern Medical School Chicago, Illinois

---

Is there a role for Allo Tx? - Against
	XIIth International Myeloma Workshop in Washington, DC Jean Paul Fermand, M.D. Hôpital Saint-Louis Paris, France

---

Is There a Place for Allogeneic Transplantation in Myeloma in the Era of Novel Agents?
	Rebuttal by Drs. Mehta and Fermand followed by Q & A Period

---

US/DFCI - New Agents
	XIIth International Myeloma Workshop in Washington, DC Kenneth Anderson. M.D. substituting for Paul Richardson, M.D. Dana-Farber Cancer Institute Boston, Massachusetts

---

Early Combination Studies - "New Combination Approaches for MM"
	XIIth International Myeloma Workshop in Washington, DC Antonio Palumbo, M.D. Ospedale San Giovanni Battista Torino, Italia

---

New Proteasome Inhibitors
	XIIth International Myeloma Workshop in Washington, DC Robert Orlowski, M.D. MD Anderson Cancer Center Houston, Texas

---

Anti Angiogenic Agents
	XIIth International Myeloma Workshop in Washington, DC Shaji Kumar, M.D. Mayo Clinic Rochester, Minnesota

---

Novel Bone Targeting Agents in Myeloma
	XIIth International Myeloma Workshop in Washington, DC Noopur Raje, M.D. Massachusetts General Hospital Cancer Center Center for Multiple Myeloma Boston, Massachusetts

---

New Imids
	XIIth International Myeloma Workshop in Washington, DC Martha Lacy, M.D. Mayo Clinic Rochester, Minnesota

---

Lenalidomide Inhibits the Multiple Myeloma Cell-Survival Factor IRF4/MUM1
	XIIth International Myeloma Workshop in Washington, DC Antonia Lopez-Girona, M.D. Celgene Corporation

---

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma
	XIIth International Myeloma Workshop in Washington, DC Marc Raab, M.D. Dana-Farber Cancer Institute Boston, Massachusetts

---

Whole Body MRI in Asymptomatic Plasma Cell Disease
	XIIth International Myeloma Workshop in Washington, DC Jens Hillengass, M.D. University of Heidelberg Heidelberg, Germany

---

Superiority of VTD Over TD Incorporated Into ASCT for Newly Diagnosed MM
	XIIth International Myeloma Workshop in Washington, DC Michele Cavo, M.D. Istituto "Seragnoli" Bologna, Italy

---